Metyrosine and pheochromocytoma

Area of Science:

• Endocrinology
• Cardiovascular Surgery
• Pharmacology

Background:

• Pheochromocytoma surgery poses risks of severe hemodynamic instability.
• Preoperative pharmacological management is crucial for mitigating these risks.

Purpose of the Study:

• To assess the impact of metyrosine (a catecholamine synthesis inhibitor) combined with alpha-blockers (prazosin or phenoxybenzamine) on cardiovascular morbidity during pheochromocytoma removal.
• To compare these treatment regimens against single-agent blockade and no preoperative medication.

Main Methods:

• Retrospective analysis of 28 years of patient data from Medical College of Georgia.
• Patients were grouped based on preoperative medication: metyrosine with prazosin, metyrosine with phenoxybenzamine, phenoxybenzamine alone, or no medication.
• Key outcomes included the percentage of patients not requiring pressors or phentolamine intraoperatively, and perioperative peak systolic pressures and heart rates.

Main Results:

• Metyrosine-treated patients showed significantly lower intraoperative peak systolic pressures (168 +/- 27 mm Hg) compared to untreated patients (243 +/- 40 mm Hg).
• 95% of patients on metyrosine avoided intraoperative pressors, versus 50% on phenoxybenzamine alone.
• 81% of metyrosine-pretreated patients avoided intraoperative phentolamine, compared to 33% with phenoxybenzamine alone and 29% with no medication. Two deaths from hypertensive crisis occurred in the untreated group.

Conclusions:

• Combining metyrosine with alpha-blockade offers superior blood pressure control and reduces the need for intraoperative antihypertensive medications and pressors compared to single-agent blockade.
• Preoperative metyrosine and alpha-blocker therapy is an effective strategy to decrease surgical morbidity in pheochromocytoma patients.
• This combined approach is particularly valuable given potential intraoperative phentolamine availability issues.